Cargando…
Olanzapine-Induced Parkinsonism and Akathisia: A Case Report
This article sheds light on the case of a 22-year-old patient with paranoid schizophrenia. A treatment regimen of olanzapine (an atypical antipsychotic) of 15 mg/day was initiated for the patient and it was associated with extrapyramidal symptoms (EPS) such as drug-induced parkinsonism (DIP) and aka...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851297/ https://www.ncbi.nlm.nih.gov/pubmed/35198269 http://dx.doi.org/10.7759/cureus.21354 |
_version_ | 1784652792902713344 |
---|---|
author | Jaitpal, Varun Gawande, Sushil |
author_facet | Jaitpal, Varun Gawande, Sushil |
author_sort | Jaitpal, Varun |
collection | PubMed |
description | This article sheds light on the case of a 22-year-old patient with paranoid schizophrenia. A treatment regimen of olanzapine (an atypical antipsychotic) of 15 mg/day was initiated for the patient and it was associated with extrapyramidal symptoms (EPS) such as drug-induced parkinsonism (DIP) and akathisia. Based on the different treatment regimens available, the patient was switched to an alternate antipsychotic along with anticholinergics, antihistamines, and benzodiazepines, following which the patient recovered well and did not report any further side effects. The highlighted case stresses the need for proper monitoring of the drug dose and sequential periodic examination of the patient to nullify the risk of adverse effects and poor compliance. |
format | Online Article Text |
id | pubmed-8851297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-88512972022-02-22 Olanzapine-Induced Parkinsonism and Akathisia: A Case Report Jaitpal, Varun Gawande, Sushil Cureus Psychiatry This article sheds light on the case of a 22-year-old patient with paranoid schizophrenia. A treatment regimen of olanzapine (an atypical antipsychotic) of 15 mg/day was initiated for the patient and it was associated with extrapyramidal symptoms (EPS) such as drug-induced parkinsonism (DIP) and akathisia. Based on the different treatment regimens available, the patient was switched to an alternate antipsychotic along with anticholinergics, antihistamines, and benzodiazepines, following which the patient recovered well and did not report any further side effects. The highlighted case stresses the need for proper monitoring of the drug dose and sequential periodic examination of the patient to nullify the risk of adverse effects and poor compliance. Cureus 2022-01-18 /pmc/articles/PMC8851297/ /pubmed/35198269 http://dx.doi.org/10.7759/cureus.21354 Text en Copyright © 2022, Jaitpal et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Psychiatry Jaitpal, Varun Gawande, Sushil Olanzapine-Induced Parkinsonism and Akathisia: A Case Report |
title | Olanzapine-Induced Parkinsonism and Akathisia: A Case Report |
title_full | Olanzapine-Induced Parkinsonism and Akathisia: A Case Report |
title_fullStr | Olanzapine-Induced Parkinsonism and Akathisia: A Case Report |
title_full_unstemmed | Olanzapine-Induced Parkinsonism and Akathisia: A Case Report |
title_short | Olanzapine-Induced Parkinsonism and Akathisia: A Case Report |
title_sort | olanzapine-induced parkinsonism and akathisia: a case report |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851297/ https://www.ncbi.nlm.nih.gov/pubmed/35198269 http://dx.doi.org/10.7759/cureus.21354 |
work_keys_str_mv | AT jaitpalvarun olanzapineinducedparkinsonismandakathisiaacasereport AT gawandesushil olanzapineinducedparkinsonismandakathisiaacasereport |